A published study, led by Sabinsa Chair and founder Dr Muhammed Majeed, evaluated the clinical efficacy and safety of Calebin A in managing weight in 40 obese or overweight individuals for 90 days
Sabinsa has launched CurCousin, a branded ingredient which contains Calebin A, a curcumin analog naturally present in Curcuma longa and Curcuma caesia.
The ingredient is designed to help balance cholesterol and support healthy blood sugar levels and circulation. It also supports a healthy body weight by inhibiting adipogenesis (fat cells). The product is clinically supported for a dosage of 25 mg twice a day. The company holds 65 US and international patents on this product, which also has self-affirmed GRAS status.
A published study, led by Sabinsa Chair and founder Dr Muhammed Majeed, evaluated the clinical efficacy and safety of Calebin A in managing weight in 40 obese or overweight individuals for 90 days. The subjects were administered one 25 mg Calebin A capsule twice a day, and after 90 says, significant reduction in body weight and body mass index were observed in the supplementation group compared with placebo. A significant change in serum biomarkers like leptin, adiponectin, and cortisol was also observed in the study subjects, with improved blood lipid profiles. Moreover, Calebin A was found to be safe and well-tolerated by all the subjects. These results suggest Calebin A is effective in managing healthy body weight by inhibiting adipogenesis and supporting metabolic health, Sabinsa says.
“Deep knowledge of curcumin has been a passion of our research teams for many years, and has resulted in industry leading ingredients like Curcumin C3 Complex,” said Dr Majeed. “We’re enthusiastic about the potential of CurCousin and eager to share details about it with our customers across the world.”